Redwood Investment Management LLC Acquires New Position in Halozyme Therapeutics, Inc. $HALO

Redwood Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 28,149 shares of the biopharmaceutical company’s stock, valued at approximately $2,203,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Measured Wealth Private Client Group LLC raised its holdings in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC boosted its stake in Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. MidFirst Bank acquired a new stake in Halozyme Therapeutics in the second quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics in the second quarter valued at about $28,000. Finally, Quantbot Technologies LP bought a new position in Halozyme Therapeutics in the second quarter valued at about $30,000. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Down 2.1%

Halozyme Therapeutics stock opened at $107.06 on Thursday. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. Halozyme Therapeutics, Inc. has a 12-month low of $61.22 and a 12-month high of $109.66. The firm’s fifty day moving average is $85.50 and its 200 day moving average is $74.39. The company has a market capitalization of $12.15 billion, a PE ratio of 31.96, a PEG ratio of 0.44 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%.The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the previous year, the company posted $1.54 earnings per share. The company’s quarterly revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HALO has been the subject of a number of research reports. TD Cowen increased their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Weiss Ratings lowered shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, August 14th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Friday, August 7th. Finally, UBS Group restated a “buy” rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Nine investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $91.20.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Mahesh Krishnan sold 7,304 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $75.00, for a total transaction of $547,800.00. Following the completion of the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. The trade was a 33.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the sale, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 64,103 shares of company stock worth $5,226,496. 2.50% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.